Sorrento Therapeutics Inc

Change company Symbol lookup

Select an option...

SRNEQ Sorrento Therapeutics Inc

SPI SPI Energy Co Ltd

AMC AMC Entertainment Holdings Inc

BOF BranchOut Food Inc

KITT Nauticus Robotics Inc

EAT Brinker International Inc

JCSE JE Cleantech Holdings Ltd

GVP GSE Systems Inc

CURV Torrid Holdings Inc

APRN Blue Apron Holdings Inc

Go

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.